Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed by a lab test on tissue or fluid samples.
• People whose cancer has not spread to distant parts of the body (no metastatic disease).
• People whose scans clearly show the cancer cannot be surgically removed because of how it is positioned around key blood vessels in the abdomen.
• People who are in good general health and able to carry out daily activities with little or no restriction (ECOG score of 0 or 1).
• People whose blood test results meet all of the following: a white blood cell count of at least 1,000/mm³, a platelet count of at least 100,000/mm³, kidney function within an acceptable range (creatinine no more than 1.5 times the normal upper limit, and creatinine clearance above 45 mL/min), and a bilirubin level of 2 mg/dL or lower.

Who may not be able to join:

• People whose pancreatic cancer is considered removable by surgery, or is in a "borderline" category for surgery.
• People who have previously had surgery to remove pancreatic cancer.
• People who have previously had radiation therapy to the abdomen in an area that would overlap with the radiation area used in this trial (prior radiation to other parts of the body is generally permitted).
• People who have had chemotherapy other than the regimens FOLFIRINOX, Gem-Abrax, or Gem-Cap (note: people currently receiving chemotherapy may still be considered for registration).
• People who experienced a severe (grade 4) side effect before starting the chemoradiation phase of the trial that may have been caused by the initial chemotherapy.
• People who needed their chemotherapy dose reduced more than twice during the initial chemotherapy phase.
• People who are currently taking certain strong medications that affect how the body processes drugs (known as strong CYP3A4 inhibitors or inducers), unless those medications are stopped at least 14 days before the trial treatment begins (confirm with trial site which medications this applies to).
• People with moderate to severe pre-existing nerve damage (grade 2 or higher neuropathy), a liver condition called Gilbert's disease, or a specific inherited genetic variation affecting drug processing (UGTA1A1*28, homozygous).
• People who are pregnant or breastfeeding, or people of childbearing age who do not have a negative pregnancy test within 14 days of joining the trial.
• People who are HIV-positive and taking combination antiretroviral therapy, due to possible interactions with the chemotherapy drugs used in this trial.
• People who did not consistently follow through with their initial chemotherapy treatment as prescribed.

Important: Always verify eligibility with the trial site directly before applying.